MARKET

CBAY

CBAY

CymaBay
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.86
-0.01
-0.17%
After Hours: 5.65 -0.21 -3.58% 16:46 09/17 EDT
OPEN
5.85
PREV CLOSE
5.87
HIGH
5.99
LOW
5.80
VOLUME
278.29K
TURNOVER
--
52 WEEK HIGH
14.00
52 WEEK LOW
4.820
MARKET CAP
402.59M
P/E (TTM)
-4.2968
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CBAY and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CBAY News

  • CymaBay Therapeutics Announces Departure of Chief Medical Officer
  • GlobeNewswire.8h ago
  • Investors in CymaBay Therapeutics Need Patience and Discipline
  • TheStreet.com.1d ago
  • Edited Transcript of CBAY earnings conference call or presentation 7-Aug-19 8:30pm GMT
  • Thomson Reuters StreetEvents.09/10 16:10
  • CymaBay Therapeutics to Present at Upcoming Investor Conferences in September
  • GlobeNewswire.09/03 13:00

More

Industry

Biotechnology & Medical Research
+0.24%
Pharmaceuticals & Medical Research
+0.57%

Hot Stocks

Name
Price
%Change

About CBAY

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company's product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout. MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta (PPARd). The Company has completed over five Phase I clinical studies and a Phase II clinical study for MBX-8025. MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes (T2DM), with a dual mechanism, including direct effects and indirect effects mediated by gastrointestinal hormones known as incretins on glucose-dependent insulin secretion, as well as potentially beneficial effects on islet health. The Company has completed over four Phase I clinical studies and a Phase II clinical study for MBX-2982.
More

Webull offers CymaBay Therapeutics Inc (CBAY) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.